AbbVie hep C combo fast-tracked in U.S. and EU; Merck's Gardasil wins new indication in Europe;

> AbbVie's ($ABBV) all-oral hep C combo has won expedited assessment in both the U.S. and the EU. Report | Article

> Europe has approved Merck's ($MRK) Gardasil vaccine to prevent anal cancer. Report

> Bristol-Myers Squibb's ($BMY) "The Pink Drive" campaign took bronze at the Goafest's Abby awards. Story

> Takeda and Affymax ($AFFY) have terminated their collaboration and license agreement on anemia drug Omontys and will withdraw their NDA. More (sub. req.)

> Roche's ($RHHBY) Gazyvaro has won Swiss approval for the therapy of patients with previously untreated chronic lymphocytic leukemia (CLL). Release

> U.K. cost watchdog NICE has given its recommendation to Sucampo Pharmaceuticals' constipation med, Amitiza. Release

> Boehringer Ingelheim has earned The Information Standard certification, commissioned by England's National Health Service, for the quality of its healthcare information. Report

And Finally... U.S. submission stumbled at the Lions Health Festival. More

Suggested Articles

Novartis is touting 52-week data for Cosentyx in spondyloarthritis—an indication where Eli Lilly's Taltz recently scored a trailblazing FDA approval.

Bristol Myers Squibb's Zeposia will leverage promising top-line phase 3 data into a possible FDA approval in the lucrative ulcerative colitis market.

Sanofi's Sarclisa is coming full-force at Johnson & Johnson blockbuster Darzalex in the multiple myeloma field—now backed by new data.